Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Gemigliptin/Dapagliflozin/Metformin Fixed-Dose Combination in Healthy Volunteers
NCT07399470Phase 1Completed
- Sponsor
- LG Chem
- Start
- Jan 2026
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemigliptin, dapagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by LG Chem. Primary endpoint: Plasma concentration of Gemigliptin, Dapagliflozin and Metformin up to 72 hours. Started Jan 2026; status: completed.
02
Drugs
gemigliptindapagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07399470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399470.